Found vs Society of You
Two GLP-1 desks, one scoreboard. We put Found and Society of You head-to-head on the published Brief Score — the same six factors, scored the same way.
Found
Society of You
The verdict
Found takes this head-to-head.
Found scores 81 to 66 on our six-factor Brief Score — The widest medication bench in the ranking — compounded, brand-name and oral orforglipron — priced off a membership rather than a sticker.
That doesn't make Society of You a bad call — it's best for shoppers who want compounded glp-1 from named partner pharmacies, including oral tirzepatide. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Found | Society of You | |
|---|---|---|
| Brief Score | 81/100 (B−) | 66/100 (C) |
| Semaglutide | $289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); the advertised $99 is the in-network INSURANCE rate and still sits before a ~$30 per-visit copay | From $279/mo (promotional rate, compounded) |
| Tirzepatide | $289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); one program price covers both molecules | From $425/mo (compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Found: Headline unchanged, but our $129 line was wrong: the published floor is $99 and it requires a 3-, 6- or 12-month plan.
Society of You: New to the tracker on 1 August 2026. The published line reads From $279/mo (promotional rate, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.